A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
Authors
Keywords
-
Journal
PLoS One
Volume 10, Issue 4, Pages e0121197
Publisher
Public Library of Science (PLoS)
Online
2015-04-03
DOI
10.1371/journal.pone.0121197
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial
- (2013) Jeffrey Infante et al. CANCER BIOLOGY & THERAPY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunomodulatory drugs in multiple myeloma
- (2013) Swati Andhavarapu et al. Expert Review of Hematology
- A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
- (2012) M. A. Dimopoulos et al. BLOOD
- Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma
- (2012) Sara Bringhen et al. Expert Opinion on Drug Metabolism & Toxicology
- Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer
- (2012) Ivan Shevchenko et al. INTERNATIONAL JOURNAL OF CANCER
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers
- (2012) Taher Abu-Hejleh et al. Current Oncology Reports
- Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
- (2011) A. Maraveyas et al. EUROPEAN JOURNAL OF CANCER
- The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer
- (2011) Mario Mandalà et al. Expert Review of Anticancer Therapy
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
- (2010) Lei Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer
- (2010) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
- (2009) Atsuko Soeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer
- (2009) Christophe Le Tourneau et al. JOURNAL OF CLINICAL ONCOLOGY
- Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development
- (2009) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
- (2008) Sharon L. Sanborn et al. INVESTIGATIONAL NEW DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now